| |
|
|
Session 78
Poster Presentations Therapeutic Vaccination Wednesday 1:30 - 3:30 pm Hall A |
| 641 | Therapeutic Vaccination Induce Strong and Long-lasting HIV-specific Cellular Immunological Responses in ART-naïve and ART-experienced HIV-1+ Individuals E. Fernandez-Cruz*1, J. Navarro1, S. Moreno2, J. Pérez Molina1, M. L. Abad1, L. Díaz1, C. Rodriguez Sainz1, J. M. Peña3, D. Podzamczer4, I. Ocaña5, B. Clotet6, M. A. Muñoz-Fernandez1, J. Gil1, J. Carbone1, J. Gonzalez-Lahoz7 1Hosp Gregorio Marañón, Madrid, Spain; 2Hosp Ramón y Cajal, Madrid, Spain; 3Hosp La Paz, Madrid, Spain; 4? CS Bellvitge; 5Hosp V Hebrón, Barcelona, Spain; 6Hosp Germans Trias i Pujol, Barcelona, Spain; and 7IS Carlos III, Madrid, Spain |
| 642 | Immunogenicity of DermaVir in Naïve and Chronically-infected Macaques J. Lisziewicz*1, J. Xu1, J. Trocio1, L. Whitman1, A. Ryder1, N. Bakare1, P. Markham2, S. Arya3, F. Lori1 1Res Inst for Genetic and Human Therapy, Washington, DC; 2Advanced BioSci Labs, Rockville, MD; and 3Natl Inst of Hlth, NCI Frederick, MD |
| 643 | CD4+ and CD8+ T-cell Responses are Induced in Chronically HIV-1 Infected Patients after Immunization by a Lipopeptide Vaccine D. Salmon1, N. Daniel1,2, G. Pialoux3, V. Schneider4, A. Krivine1, B. Charmeteau2, C.Troadec2, J-G Guillet2, H. Gahery-Segard*2 1Cochin Hosp, Paris, France; 2INSERM U567, Paris, France; 3Tenon Hosp, Paris, France; and 4Rothschid Hosp, Paris, France |
| 644 | Safety and Immunogenicity of an HIV-1 Tat Toxoid Vaccine in HIV-1 Infected Volunteers on HAART P. Hermans*1, M. J. Frachette2, D. Blanc2, F. Boudet2, M. Chevalier2, N. Nougarède2, O. Pitiot2, D. Notté1, B. Poll1, K. Kabeya1, K. Willard-Gallo3, M. Klein4, N. Clumeck1 1CHU St Pierre, Brussels, Belgium; 2Aventis Pasteur, Lyon, France; 3Inst Jules Bordet, Brussels, Belgium; and 4Canadian Network for Vaccines and Immunotherapeutics, Montreal, Canada |
| 645 | Safety amd Immunogenicity of a Candidate HIV-1 DNA Gag/Multi-epitope Vaccine, pTHr.HIVA, in HIV-1 Seropositive Subjects Receiving HAART L. Dorrell*1, H. Yang1, C. P. Conlon2, T. Hanke1, A. Suttill3, M. Lancaster3, A. Edwards3, S. L. Rowland-Jones1, A. J. McMichael1 1Med Res Council Human Immun Unit, Oxford, UK; 2John Radcliffe Hosp, Oxford, UK; and 3Harrison Dept, Radcliffe Infirmary, Oxford, UK |
| 646 | Cross Recognition of HIV-specific CD8 Responses in Chronically HIV-1 Infected Patients Immunized by an HIV-1-LAI Recombinant Canarypox Vector (vCP1433) M. Le Garff*1, K. Gourlain1, R.Tubiana1, P. Haas1, C. Rabian2, T. Decoville1, C. Dalban1, M. Labalette 3, D. Olive4, V. Calvez1, P. Debre1, C. Katlama1, B. Autran 1, G. Carcelain1 1Pitié-Salpêtrière Hosp, Paris, France; 2St Louis Hosp, Paris, France; 3Univ Hosp, Lille, France; and 4Inst Paoli Calmettes, Marseille, France |
| 647 | ELISPOT Responses to Highly Conserved, HLA-supertype Epitopes in HIV-1: Implications for Therapeutic Vaccination C. Wilson*1, M. Anders1, S. MaWhinney1, J. Forster1, M. Newman2, D. McKinney2, B. Livingston2 1Univ of Colorado Hlth Sci Ctr, Denver and 2Epimmune, San Diego, CA |
| 647a | Therapeutic Vaccination Requires Highly Active Antiretroviral Therapy J Lisziewicz *1, J Xu1, M Lewis2, J Trocio1, L Whitman1, F Lori1 1Research Institute for Genetic and Human Therapy, Washington DC and 2Southern Research Institute, Frederick, MD |